Questions: Coagulation Cascade: Tissue Factor Pathway and Thrombin Generation

Question 1

A patient is found to have Factor V Leiden — a mutation making factor Va resistant to degradation by protein C. What is the most direct pathophysiological consequence?

• A. Impaired fibrin cross-linking, causing structurally weak clots
• B. Failure to generate thrombin, producing a bleeding tendency
• C. Persistent procoagulant amplification due to uninhibited factor Va, predisposing to thrombosis
• D. Overactivation of TFPI, which paradoxically amplifies the TF:VIIa complex

Answer: (C)

Protein C normally degrades factors Va and VIIIa — two critical cofactors in the amplification loops that sustain thrombin generation. When factor Va is resistant to this degradation, the prothrombinase complex (factor Xa + Va) remains active far longer than normal, producing excess thrombin. This persistent procoagulant state — not a failure to clot — is why Factor V Leiden is a hypercoagulable condition that predisposes to DVT and pulmonary embolism, not bleeding.

Question 2

Why does rupture of an atherosclerotic plaque so rapidly trigger massive clot formation?

• A. The plaque exposes collagen, which directly polymerizes fibrin without enzymatic steps
• B. The lipid-rich necrotic core is packed with tissue factor, massively activating the extrinsic pathway upon contact with blood
• C. Plaque rupture releases stored thrombin directly into the circulation
• D. Plaque rupture activates the contact (intrinsic) pathway through factor XII exposure to lipids

Answer: (B)

Tissue factor is the master initiator of the coagulation cascade in vivo. Subendothelial cells (smooth muscle, fibroblasts) normally express TF but are shielded from blood by intact endothelium. The necrotic core of an atherosclerotic plaque contains unusually high concentrations of TF. When the plaque ruptures, this TF is suddenly exposed to circulating factor VII, forming TF:VIIa and triggering rapid amplification through the common pathway — explaining the abrupt onset of arterial thrombosis in acute myocardial infarction.

Question 3

Tissue factor is constitutively expressed on the luminal surface of healthy endothelial cells, making the vasculature perpetually primed for clotting.

• T. True
• F. False

Answer: False

The opposite is true: healthy endothelium acts as a barrier that keeps TF (expressed on subendothelial cells) hidden from blood. Endothelial cells also actively produce anticoagulant factors and express thrombomodulin to activate protein C. TF exposure requires vascular injury or inflammatory endothelial activation. The barrier function of the endothelium is precisely what prevents spontaneous intravascular coagulation.

Question 4

Thrombin's positive feedback loops — activating factors V, VIII, and XI — explain why a small initial TF stimulus can generate a disproportionately large fibrin clot.

• T. True
• F. False

Answer: True

This amplification is a defining feature of cascade design. A trace amount of TF:VIIa activates factors X and IX, generating a small initial burst of thrombin. That thrombin then activates cofactors V and VIII, which dramatically accelerate further thrombin production in a self-amplifying loop. This is the same logic as a chain reaction: small input → exponential output. Anticoagulant proteins (antithrombin III, protein C, TFPI) are the brakes that keep this localized to the injury site.

Question 5

Why is the coagulation cascade described as an 'amplification system,' and what does this mean for both its physiological purpose and its pathological potential?

Model answer: Each step in the cascade converts an inactive zymogen into an active enzyme that can activate many molecules of the next zymogen — so the signal is amplified at every stage. Even a trace amount of tissue factor can produce a massive fibrin clot within seconds. Physiologically, this is essential: hemostasis requires a fast, decisive, localized response. Pathologically, the same amplification means that inappropriate activation — from ruptured atherosclerotic plaque, systemic infection, or genetic loss of anticoagulant control — can generate runaway clotting that occludes vessels or consumes clotting factors systemically (DIC).

The cascade trades precision for speed. Anticoagulant proteins (antithrombin III, protein C, TFPI) are the precision mechanisms that keep the speed from becoming catastrophic. Understanding coagulopathy requires thinking in terms of this balance: pathology arises either from excess activation of the procoagulant side or from deficiency of the anticoagulant side, and these produce opposite clinical syndromes (thrombosis vs. hemorrhage).